Empirical Asset Management LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,863 shares of the medical research company's stock, valued at approximately $34,784,000. Thermo Fisher Scientific accounts for 1.0% of Empirical Asset Management LLC's portfolio, making the stock its 21st biggest holding.
A number of other large investors have also bought and sold shares of TMO. Eagle Rock Investment Company LLC grew its holdings in Thermo Fisher Scientific by 0.3% in the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after acquiring an additional 19 shares during the last quarter. Cohen Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 2.5% in the fourth quarter. Cohen Investment Advisors LLC now owns 4,976 shares of the medical research company's stock worth $2,589,000 after purchasing an additional 122 shares during the last quarter. Carnegie Investment Counsel increased its holdings in Thermo Fisher Scientific by 1.2% during the 4th quarter. Carnegie Investment Counsel now owns 58,951 shares of the medical research company's stock valued at $30,668,000 after purchasing an additional 726 shares during the period. Gateway Investment Advisers LLC lifted its holdings in Thermo Fisher Scientific by 1.3% in the 4th quarter. Gateway Investment Advisers LLC now owns 77,897 shares of the medical research company's stock worth $40,525,000 after buying an additional 1,027 shares during the period. Finally, Mirador Capital Partners LP increased its stake in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Mirador Capital Partners LP now owns 8,549 shares of the medical research company's stock valued at $4,448,000 after buying an additional 58 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,150 shares of company stock worth $25,954,465. Insiders own 0.34% of the company's stock.
Shares of TMO opened at $561.51 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The business's fifty day simple moving average is $529.69 and its two-hundred day simple moving average is $568.01. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $214.78 billion, a price-to-earnings ratio of 35.20, a P/E/G ratio of 3.59 and a beta of 0.76.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the company earned $5.69 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.
Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's board believes its shares are undervalued.
The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.
Several research firms recently weighed in on TMO. Morgan Stanley cut their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an "overweight" rating on the stock in a report on Monday. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a "buy" rating and a $680.00 price target on the stock. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a research report on Wednesday, October 23rd. TD Cowen raised their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Finally, Wells Fargo & Company reduced their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating on the stock in a research note on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $648.95.
Read Our Latest Stock Report on Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.